Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data  Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Click here to get full coverage on Trend Tracker for (ALDX) - news.stocktradersdaily.com

Trend Tracker for (ALDX)  news.stocktradersdaily.com

Trend Tracker for (ALDX) - news.stocktradersdaily.com

Click here to get full coverage on Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan

Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection  Stock Titan

Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan

Click here to get full coverage on Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman - PR Newswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman  PR Newswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman - PR Newswire

Click here to get full coverage on Aldeyra Therapeutics Holds Annual Meeting with Key Votes - TipRanks

Aldeyra Therapeutics Holds Annual Meeting with Key Votes  TipRanks

Aldeyra Therapeutics Holds Annual Meeting with Key Votes - TipRanks

Click here to get full coverage on Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference  Business Wire

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire

Click here to get full coverage on $ALDX stock is up 11% today. Here's what we see in our data. - Nasdaq

$ALDX stock is up 11% today. Here's what we see in our data.  Nasdaq

$ALDX stock is up 11% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance

Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?  Yahoo Finance

Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven?  simplywall.st

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - simplywall.st

Click here to get full coverage on Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N  GuruFocus

Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus

Click here to get full coverage on FDA Green Lights Aldeyra's Novel Eye Cancer Drug Trial Design - Potential First Approved PVRL Treatment - Stock Titan

FDA Green Lights Aldeyra's Novel Eye Cancer Drug Trial Design - Potential First Approved PVRL Treatment  Stock Titan

FDA Green Lights Aldeyra's Novel Eye Cancer Drug Trial Design - Potential First Approved PVRL Treatment - Stock Titan

Click here to get full coverage on ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire

ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock  GlobeNewswire

ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire

Click here to get full coverage on Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity  Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Click here to get full coverage on When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com

When the Price of (ALDX) Talks, People Listen  news.stocktradersdaily.com

When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com

Click here to get full coverage on Insider Sale: 10% owner at $ALDX Sells 3,400,000 Shares - Nasdaq

Insider Sale: 10% owner at $ALDX Sells 3,400,000 Shares  Nasdaq

Insider Sale: 10% owner at $ALDX Sells 3,400,000 Shares - Nasdaq

Click here to get full coverage on ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap  Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Click here to get full coverage on ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm  PR Newswire

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

Click here to get full coverage on FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan - Stock Titan

FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan  Stock Titan

FDA Denial Forces Aldeyra Back to Trials: Key Details on $101M Cash Position and 2025 Resubmission Plan - Stock Titan

Click here to get full coverage on Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st

Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early  simplywall.st

Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st

Click here to get full coverage on After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX)  Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

Click here to get full coverage on (ALDX) Investment Analysis and Advice - news.stocktradersdaily.com

(ALDX) Investment Analysis and Advice  news.stocktradersdaily.com

(ALDX) Investment Analysis and Advice - news.stocktradersdaily.com

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX - PR Newswire

Click here to get full coverage on June 2025's Spotlight On Promising Penny Stocks - simplywall.st

June 2025's Spotlight On Promising Penny Stocks  simplywall.st

June 2025's Spotlight On Promising Penny Stocks - simplywall.st

Click here to get full coverage on Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter  Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection - GuruFocus

Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection  GuruFocus

Aldeyra Therapeutics (ALDX) Plummets 74% After FDA Rejection - GuruFocus

Click here to get full coverage on Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA  Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus

Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey  GuruFocus

Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus

Click here to get full coverage on SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit  ACCESS Newswire

SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Click here to get full coverage on (ALDX) Trading Report - news.stocktradersdaily.com

(ALDX) Trading Report  news.stocktradersdaily.com

(ALDX) Trading Report - news.stocktradersdaily.com

Click here to get full coverage on Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News  GuruFocus

Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - simplywall.st

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?  simplywall.st

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? - simplywall.st

Click here to get full coverage on Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX - Business Wire

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX  Business Wire

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX - Business Wire

Click here to get full coverage on INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire

INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC  GlobeNewswire

INVESTOR ALERT: Investigation of Aldeyra Therapeutics, Inc. (ALDX) Announced by Holzer & Holzer, LLC - GlobeNewswire

Click here to get full coverage on Aldeyra Therapeutics Achieves Success in Phase 3 Trial - TipRanks

Aldeyra Therapeutics Achieves Success in Phase 3 Trial  TipRanks

Aldeyra Therapeutics Achieves Success in Phase 3 Trial - TipRanks

Click here to get full coverage on Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (ALDX) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com

Aldeyra therapeutics sees $4.83 million stock sale by major shareholder  Investing.com

Aldeyra therapeutics sees $4.83 million stock sale by major shareholder - Investing.com

Click here to get full coverage on Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191 - TipRanks

Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191  TipRanks

Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191 - TipRanks

Click here to get full coverage on Aldeyra Resubmits Reproxalap NDA to FDA - TipRanks

Aldeyra Resubmits Reproxalap NDA to FDA  TipRanks

Aldeyra Resubmits Reproxalap NDA to FDA - TipRanks

Click here to get full coverage on Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal - Stock Titan

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal  Stock Titan

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal - Stock Titan

Click here to get full coverage on Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News  GuruFocus

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus

Click here to get full coverage on Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com

Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback  Investing.com

Laidlaw maintains Buy on Aldeyra, sees upside despite FDA setback - Investing.com

Click here to get full coverage on Aldeyra receives FDA special protocol assessment for lymphoma treatment By Investing.com - Investing.com Nigeria

Aldeyra receives FDA special protocol assessment for lymphoma treatment By Investing.com  Investing.com Nigeria

Aldeyra receives FDA special protocol assessment for lymphoma treatment By Investing.com - Investing.com Nigeria

Click here to get full coverage on BTIG cuts Aldeyra Therapeutics target to $9, keeps Buy rating - Investing.com

BTIG cuts Aldeyra Therapeutics target to $9, keeps Buy rating  Investing.com

BTIG cuts Aldeyra Therapeutics target to $9, keeps Buy rating - Investing.com

Click here to get full coverage on Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener

Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell  MarketScreener

Aldeyra Therapeutics Resubmits New Drug Application For Dry Eye Drug; Shares Up Pre-Bell - MarketScreener

Click here to get full coverage on Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks

Aldeyra Therapeutics Receives FDA Complete Response Letter  TipRanks

Aldeyra Therapeutics Receives FDA Complete Response Letter - TipRanks

Click here to get full coverage on Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN

Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design  MSN

Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN

Click here to get full coverage on Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission - Investing.com

Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission  Investing.com

Aldeyra Therapeutics sets sights on mid-2025 for NDA resubmission - Investing.com

Click here to get full coverage on Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next?  timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Click here to get full coverage on Aldeyra Therapeutics Receives Special Protocol Assessment Agreem - GuruFocus

Aldeyra Therapeutics Receives Special Protocol Assessment Agreem  GuruFocus

Aldeyra Therapeutics Receives Special Protocol Assessment Agreem - GuruFocus

Click here to get full coverage on Kirby McInerney LLP Announces Investigation of Possible - GlobeNewswire

Kirby McInerney LLP Announces Investigation of Possible  GlobeNewswire

Kirby McInerney LLP Announces Investigation of Possible - GlobeNewswire

Click here to get full coverage on Aldeyra Therapeutics Investors With Significant Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - ALDX - ACCESS Newswire

Aldeyra Therapeutics Investors With Significant Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - ALDX  ACCESS Newswire

Aldeyra Therapeutics Investors With Significant Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - ALDX - ACCESS Newswire

Click here to get full coverage on Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic  Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Click here to get full coverage on Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm  GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire

Click here to get full coverage on Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

Aldeyra DED phase III hits but reproxalap field goal fumbled  BioWorld MedTech

Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech

Click here to get full coverage on Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating Organon,  GlobeNewswire

Aldeyra The (ALDX)

Price Chart

Key Statistics

Technicals

About ALDX

Latest News

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Trend Tracker for (ALDX) - news.stocktradersdaily.com

Aldeyra's Dry Eye Drug Hits Major Trial Goal (P=0.002), FDA Application Resubmitted After Previous Rejection - Stock Titan

Advanced Charts

Top Gainers

Top Losers